twixbio

About us

TwixBio dedicated itself to simplifying the methods of pet cancer early detection and improving pet cancer monitoring. Launched a series of first-in-class blood-based pan-cancer tests in canines, which utilize a novel technology that is based on next-generation sequencing and artificial intelligence.
Products

PetCanSeek^®
PetCanSeek^® has been developed as a first-in-class (in China) pan-cancer detection test for canines that takes a panoramic view of blood cell-free cancer signatures of canines by shallow whole genome sequencing (sWGS), equipped with proprietary AI- and big data- driven PCS (pet cancer score) algorithm, to detect the signal of cancer at an early stage.

PetCanCure^®
PetCanCure^® is applied to monitoring cancer recurrence and risk evaluation for post-op cancer dogs. By monitoring the variation of cancer genome in cell-free DNA (cfDNA) of post-op cancer dogs continually, equipping with big data and artificial intelligence, it evaluates cancer recurrence index (CRI).

PetCanClarity^®
PetCanClarity^® is a pan-cancer pan-indication treatment response monitoring test for dogs, which is based on 4ml of peripheral blood and mapping the panoramic cancer genome by shallow whole-genome sequencing (sWGS) data. It evaluates the copy number aberration (CNA) and fragment size (FS) to calculate molecular tumor burden (MTB) and to access the therapeutic efficacy for the late-stage cancer dogs in the course of treatment.